$1.14
+0.03 (+2.70%)
Open$1.14
Previous Close$1.11
Day High$1.16
Day Low$1.12
52W High$2.46
52W Low$0.81
Volume—
Avg Volume51.8K
Market Cap18.67M
P/E Ratio—
EPS$-0.90
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,327.2% upside
Current
$1.14
$1.14
Target
$16.27
$16.27
$12.16
$16.27 avg
$21.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.80M | 5.18M | 3.86M |
| Net Income | -13,014,397 | -15,981,658 | -155,305 |
| Profit Margin | -343.0% | -325.8% | -4.0% |
| EBITDA | -13,790,838 | -17,875,966 | -205,551 |
| Free Cash Flow | — | — | -168,121 |
| Rev Growth | -26.7% | -26.7% | +19.6% |
| Debt/Equity | — | — | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |